Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

bioAffinity Technologies Inc. Warrant

Company price
0.1581 USD 0.01 ( 4.15%)
Last update at 2026-11-20T20:21:00Z
VOLUME
751
Market Cap
0.00M

Momentum Score

…

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.15
Low
0.16
High
52 Week Price Range
0.05
Low
2.90
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.15
Dividend Yield
-
Revenue TTM
7.32M
Revenue Per Share
0.74
Gross Profit TTM
0.00M
Debt / Equity
0.33
ROE
-151.52%
Net Debt
-1.24M
ROCE
-133.47%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -7.92M -8.15M -6.32M -7.27M -3.30M
Net income -7.94M -8.15M -6.33M -7.27M -3.31M
Selling general administrative 6.79M 2.73M 0.88M 0.99M -
Gross profit 0.54M 0.00M -0.00M -0.02M -0.04M
Reconciled depreciation 0.11M 0.01M 0.00M 0.02M -
Ebit -7.97M -4.01M -2.21M -2.60M -3.09M
Ebitda -7.72M -5.82M -1.48M -6.86M -3.05M
Depreciation and amortization 0.25M -1.81M 0.73M -4.26M 0.04M
Operating income -7.97M -4.01M -2.21M -2.60M -3.09M
Other operating expenses 10.51M 4.02M 2.21M 2.60M 3.09M
Interest expense 0.04M 2.53M 1.00M 0.38M 0.21M
Tax provision 0.02M 0.00M 0.00M 0.00M -
Interest income 0.15M 0.05M 0.00M 0.00M -
Net interest income 0.05M -2.49M -1.00M -0.38M -
Income tax expense 0.02M 0.00M 0.00M 0.00M 0.00M
Total revenue 2.53M 0.00M 0.00M 0.00M -
Total operating expenses 8.52M 4.02M 2.21M 2.60M 3.05M
Cost of revenue 1.99M 0.00M 0.00M 0.02M 0.04M
Total other income expense net 0.06M -4.14M -4.12M -4.66M -0.21M
Net income from continuing ops -7.24M -8.15M -6.33M -7.27M -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 8.22M 12.18M 1.45M 0.15M 0.66M
Intangible assets 0.83M - - - -
Other current assets 0.32M 0.12M 0.00M 0.01M 0.04M
Total liab 3.37M 1.14M 17.24M 15.22M 4.69M
Total stockholder equity 4.86M 11.04M -15.79M -15.07M -4.04M
Other current liab 1.15M 0.54M 1.60M 0.98M 0.58M
Common stock 0.07M 0.06M 0.02M 0.02M 0.02M
Capital stock 0.07M 0.06M 0.02M 0.02M -
Retained earnings -44.60M -36.67M -28.51M -22.19M -14.92M
Good will 1.40M - - - -
Cash 2.82M 11.41M 1.36M 0.08M 0.58M
Total current liabilities 2.25M 1.14M 13.04M 11.12M 4.69M
Current deferred revenue 0.03M - - - -
Net debt -1.24M -11.16M 10.00M 9.92M 3.43M
Short term debt 0.46M 0.25M 11.20M 9.95M 4.01M
Short long term debt - 0.25M 11.20M 9.95M -
Short long term debt total 1.58M 0.25M 11.36M 10.01M 4.01M
Other stockholder equity 49.39M -12134.47M 12.70M 7.10M 6.84M
Total current assets 3.97M 11.96M 1.44M 0.12M 0.62M
Net receivables 0.81M 0.01M 0.00M 0.00M 0.00M
Long term debt - - 0.16M 0.05M -
Inventory 0.02M 0.01M 0.07M 0.03M -
Accounts payable 0.60M 0.35M 0.23M 0.19M 0.10M
Accumulated other comprehensive income - - - - -0.02M
Non currrent assets other 0.02M 0.01M 0.01M 0.02M 0.01M
Non current assets total 4.25M 0.22M 0.02M 0.03M 0.04M
Capital lease obligations 1.58M - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -2.44M -0.22M 0.00M -0.00M -
Total cash from financing activities -0.34M 14.34M 3.33M 1.72M 2.33M
Net income -7.94M -8.15M -6.33M -7.27M -3.31M
Change in cash -8.59M 10.05M 1.28M -0.50M -0.17M
Begin period cash flow 11.41M 1.36M 0.08M 0.58M 0.75M
End period cash flow 2.82M 11.41M 1.36M 0.08M 0.58M
Total cash from operating activities -6.04M -4.07M -2.05M -2.21M -2.49M
Issuance of capital stock 0.00M 6.03M 0.00M - -
Depreciation 0.25M 0.01M 0.00M 0.02M 0.04M
Dividends paid - 0.00M - - -
Change to inventory -0.01M -0.01M 0.00M - -
Change to account receivables 0.31M -0.01M - - 0.00M
Sale purchase of stock - -0.00M - - -
Other cashflows from financing activities -0.34M 9.01M 6.83M 3.43M -0.01M
Capital expenditures 0.02M 0.22M 0.00M 0.00M 0.01M
Change in working capital 0.90M 0.11M 0.63M 0.48M 0.32M
Stock based compensation 0.75M 0.25M 0.04M 0.28M -
Other non cash items 0.96M 3.71M -0.24M 4.28M 0.58M
Free cash flow -6.06M -4.29M -2.05M -2.21M -2.50M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
BIAFW
bioAffinity Technologies Inc. Warrant
0.01
4.15%
0.16 - - - -
TMO
Thermo Fisher Scientific Inc
-17.51
2.54%
671.24 34.71 23.87 4.62 4.43
DHR
Danaher Corporation
-0.25
0.11%
220.36 29.09 28.01 5.67 3.20
WUXIF
WuXi AppTec Co. Ltd
-
-%
23.77 22.29 17.95 1.53 5.98
WUXAY
WuXi AppTec Co. Ltd
-0.92
3.87%
22.85 23.28 18.73 1.51 6.24

Profile*

bioAffinity Technologies Inc. Warrant

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.

22211 West Interstate 10, San Antonio, TX, United States, 78257

210 698 5334

75

Name Title Year Born
Ms. Maria Zannes J.D. Founder, Pres, CEO & Director 1956
Dr. Vivienne I. Rebel M.D., Ph.D. Exec. VP and Chief Medical & Science Officer 1965
Mr. Michael Edwards CPA, M.B.A. Chief Financial Officer 1967
Mr. Xavier T. Reveles M.S. VP of Operations NA
Mr. Timothy P. Zannes J.D. Exec. VP, Sec. & Gen. Counsel 1953
Dr. William Bauta Ph.D. Sr. VP of Therapeutics NA
Mr. Steven Girgenti Founder & Executive Chairman of the Board 1946
Ms. Maria Zannes J.D. Founder, President, CEO & Director 1956
Mr. Michael Dougherty C.P.A., M.B.A. VP & CFO 1979
Mr. Xavier T. Reveles M.S. Chief Operating Officer 1970

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…